PULM (pulmatrix.com) Market Value to Book Value Ratio

Official company branding of Pulmatrix Inc (PULM)

This daily price chart for Pulmatrix, Inc. (PULM), whose biopharmaceutical operations rely on stable demand but depend on uninterrupted raw material imports, reflects the value 3.29. In the respiratory devices segment, the firm competes for market share against resource-rich behemoths, while the business faces uncertainty regarding the timing of patent-derived profits and significant ongoing research expenditures.

PULM Pulmatrix Corporation: Market Value to Book Value in the range 07/04/2022 - 10/27/2026
Original product of Pulmatrix Corp

An investor determines an asset's margin of safety by comparing the market price to the actual net asset value. The pharmaceutical line robotics of Pulmatrix, Inc. (PULM) create a high-tech asset base that impacts the book value. The trend of the market-to-book ratio demonstrates the premium or discount coefficient to equity. A value above one confirms market confidence in future earnings, while a low level indicates undervaluation. This metric classifies the asset by its degree of fundamental risk.

Main competitors

HLN (Haleon plc) - Market Value to Book Value Ratio|KVUE (kenvue.com) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio EXOZ|Oramed Pharmaceuticals (ORMP) - Market Value to Book Value Ratio|Market Value to Book Value ENTX (enterabio.com)|MindWalk Holdings Inc. (HYFT) - Market Value to Book Value Ratio|ABVC - Market Capitalization to Net Assets|Cumberland Pharma - Market Cap to Net Assets Ratio|QNTM: Market Capitalization to Book Value Ratio|FibroGen, Inc. (FGEN) - Market Value to Book Value Ratio|TELO (telomirpharma.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio RANI|Market Cap to Net Assets Ratio Synergy CHC Corporation|Market Capitalization to Book Value Ratio RLYB|Market Capitalization to Book Value Ratio lexariabioscience.com LEXX|Market Cap to Net Assets Ratio Pheton Holdings (PTHL)|Aptorum Group Ltd - Market Cap to Book Value Multiple|Market Value to Book Value Ratio Lyra Therapeutics (LYRA)|IBO - Market Value to Book Value|tnfpharma.com - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value cbdMD|Market Cap to Net Assets Ratio PainReform Ltd. (PRFX)|Capitalization to Book Value Ratio Auris Medical (CYTO)|Lipella Pharmaceuticals, Inc. (LIPO) - Market Cap to Net Assets Ratio|Market Value to Book Value OptiNose Inc (OPTN)|Market Capitalization to Book Value Ratio PIRS|Procaps Group Corp - Market Capitalization to Book Value|Petros Pharmaceuticals (PTPI) - Market Value to Book Value Ratio|QLI - Capitalization to Book Value Ratio|SLRN (ACELYRIN) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio TFF Pharmaceuticals Inc.